Acta Med. 2023, 66: 101-106

https://doi.org/10.14712/18059694.2024.1

Triple Combination with Direct Acting Antivirals in the Treatment of Hepatitis C Does not Prolong the QT Interval

Jakub Šimkaa, Radek Pudila, Monika Fialováa, Filip Varhaníka, Stanislav Plíšekb, Petr Pařízeka

a1st Department of Internal Medicine – Cardiology and Angiology, University Hospital Hradec Králové and Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
bDepartment of Infectious Diseases, University Hospital Hradec Králové and Charles University, Faculty of Medicine in Hradec Králové, Czech Republic

Received September 30, 2023
Accepted January 3, 2024

References

1. Lauer GM, Walker BD. Hepatitis C Virus Infection. N Engl J Med 2001; 345(1): 41–52. <https://doi.org/10.1056/NEJM200107053450107>
2. González-Grande R. New approaches in the treatment of hepatitis C. WJG 2016; 22(4): 1421. <https://doi.org/10.3748/wjg.v22.i4.1421> <PubMed>
3. Popescu C, Arama V, Gliga S. Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis – Case report. BMC Gastroenterol 2011; 11(1): 30. <https://doi.org/10.1186/1471-230X-11-30> <PubMed>
4. Sakabe M, Yoshioka R, Fujiki A. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases 2013; 8(6): 173–5. <https://doi.org/10.1016/j.jccase.2013.08.002> <PubMed>
5. Zhao W, Ji F, Yu S, Li Z, Deng H. Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review. Braz J Infect Dis 2014; 18(1): 110–3. <https://doi.org/10.1016/j.bjid.2013.05.014> <PubMed>
6. Almawardy R, Elhammady W, Mousa N, Abotaleb S. Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function? Hepat Mon 2012; 12(8).
7. Poordad F, McCone J, Bacon BR, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med 2011; 364(13): 1195–206. <https://doi.org/10.1056/NEJMoa1010494> <PubMed>
8. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. N Engl J Med 2011; 364(25): 2405–16. <https://doi.org/10.1056/NEJMoa1012912>
9. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384(9941): 414–26. <https://doi.org/10.1016/S0140-6736(14)60538-9>
10. Porta‐Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. JAHA 2017; 6(12): e007724. <https://doi.org/10.1161/JAHA.117.007724> <PubMed>
11. Vandenberk B, Vandael E, Robyns T, et al. Which QT Correction Formulae to Use for QT Monitoring? JAHA 2016; 5(6): e003264. <https://doi.org/10.1161/JAHA.116.003264> <PubMed>
12. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9: 676–82. <https://doi.org/10.1038/nmeth.2019> <PubMed>
13. Liang TJ, Ghany MG. Current and Future Therapies for Hepatitis C Virus Infection. N Engl J Med 2013; 368(20): 1907–17. <https://doi.org/10.1056/NEJMra1213651> <PubMed>
14. Garcias-Ladaria J, Pérez-Ferriols A, Ortega-García P, Diago M. Dermatitis por telaprevir: manejo con corticoides orales en casos refractarios. Actas Dermo-Sifiliográficas 2014; 105(9): e55–e60. <https://doi.org/10.1016/j.ad.2013.12.023>
15. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. Gastroenterology 2014; 147(1): 132–142.e4. <https://doi.org/10.1053/j.gastro.2014.03.051>
16. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015; 22(9): 691–700. <https://doi.org/10.1111/jvh.12375> <PubMed>
17. Biomy R, Abdelshafy M, Abdelmonem A, et al. Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. Clin Med Insights Cardiol 2017; 11: 1–9. <https://doi.org/10.1177/1179546817713204> <PubMed>
18. Malik M. Problems of Heart Rate Correction in Assessment of Drug-Induced QT Interval Prolongation. J Cardiovasc Electrophysiol 2001; 12(4): 411–20. <https://doi.org/10.1046/j.1540-8167.2001.00411.x>
19. Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice: Clinical assessment of drug-induced QT prolongation. Br J Clin Pharmacol 2013; 76(1): 48–57. <https://doi.org/10.1111/bcp.12040> <PubMed>
20. Malik M, Camm AJ. Evaluation of Drug-Induced QT Interval Prolongation: Implications for Drug Approval and Labelling. Drug Safety 2001; 24(5): 323–51. <https://doi.org/10.2165/00002018-200124050-00001>
21. Goldenberg I, Moss AJ, Zareba W. QT Interval: How to Measure It and What Is “Normal.” J Cardiovasc Electrophysiol 2006; 17(3): 333–6. <https://doi.org/10.1111/j.1540-8167.2006.00408.x>
22. Malik M, Hnatkova K, Batchvarov V. Differences Between Study-Specific and Subject-Specific Heart Rate Corrections of the QT Interval in Investigations of Drug Induced QTc Prolongation. Pacing and Clinical Electrophysiology 2004; 27(6p1): 791–800. <https://doi.org/10.1111/j.1540-8159.2004.00530.x>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive